Targeted therapy shows promise for HER2-mutant NSCLC, other solid tumors

The novel HER2-targeted antibody-drug conjugate fam-trastuzumab deruxtecan-nxki appeared active in a cohort of patients with various heavily pretreated HER2-expressing or HER2-mutant solid tumors, according to results of a dose-expansion study published in Cancer Discovery.The agent demonstrated particularly promising antitumor activity among patients with HER2-mutant non-small cell lung cancer.Researchers identified interstitial lung disease as an important — and potentially serious — adverse event that requires careful monitoring and prompt intervention, but the efficacy resultsRead More

Share on facebook
Share on twitter
Share on linkedin